Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.

Citation:
I, W., S. G, Qaqish R, E. G, Yosry, A, H. M, S. R, Mohey M, Allam N, Z. N, et al., "Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.", The Lancet Gastroenterology & Hepatology , vol. 2016 Sept.;1, issue (1), pp. 36–44., 2016.